Financial Performance - Ocugen, Inc. reported research and development expenses of $10.7 million for Q4 fiscal 2025 and total R&D expenses for the year at $39.8 million [1] - General and administrative costs for Q4 were $6.1 million, with total G&A expenses for the year amounting to $27.6 million [1] - The net loss per common share for Q4 was $0.06, while the annual net loss per share was reported at $0.23 [1] Cash Position - The company stated that its cash and cash equivalents are expected to support operations into Q4 of 2026, with a potential extension into Q2 of 2027 if warrants are exercised [3] Regulatory and Development Plans - Ocugen reaffirmed its target to file three Biologics License Applications (BLAs) over the next three years, with a rolling BLA submission expected to begin in Q3 of 2026 [4] - Commercialization of OCU400 is anticipated in 2027, and topline Phase II/III data for OCU410ST is expected in Q2 of 2027 [4] - The Phase III trial for OCU410 is projected to start in 2026, with full Phase II data for OCU410 set to be reported this month [4] Company Overview - Ocugen, Inc. is a biopharmaceutical company focused on the development, discovery, and commercialization of biologics, innovative gene and cell therapies, and vaccines [5]